100 related articles for article (PubMed ID: 27485632)
1. Dual pharmacological inhibition of glutathione and thioredoxin systems synergizes to kill colorectal carcinoma stem cells.
Tanaka G; Inoue K; Shimizu T; Akimoto K; Kubota K
Cancer Med; 2016 Sep; 5(9):2544-57. PubMed ID: 27485632
[TBL] [Abstract][Full Text] [Related]
2. Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma.
Raninga PV; He Y; Datta KK; Lu X; Maheshwari UR; Venkat P; Mayoh C; Gowda H; Kalimutho M; Hooper JD; Khanna KK
Mol Ther; 2023 Mar; 31(3):729-743. PubMed ID: 36560881
[TBL] [Abstract][Full Text] [Related]
3. Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.
Onodera T; Momose I; Adachi H; Yamazaki Y; Sawa R; Ohba SI; Kawada M
J Biol Chem; 2020 Dec; 295(49):16678-16690. PubMed ID: 32978257
[TBL] [Abstract][Full Text] [Related]
4. Thioredoxin system in colorectal cancer: Its role in carcinogenesis, disease progression, and response to treatment.
Abdullah NA; Md Hashim NF; Muhamad Zakuan N; Chua JX
Life Sci; 2024 Jul; 348():122711. PubMed ID: 38734065
[TBL] [Abstract][Full Text] [Related]
5. A Glutathione-Nrf2-Thioredoxin Cross-Talk Ensures Keratinocyte Survival and Efficient Wound Repair.
Telorack M; Meyer M; Ingold I; Conrad M; Bloch W; Werner S
PLoS Genet; 2016 Jan; 12(1):e1005800. PubMed ID: 26808544
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin Reductase Inhibitor Suppresses the Local Progression of Rhabdomyosarcoma With PDX Models.
Kinoshita H; Kinoshita S; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
Cancer Genomics Proteomics; 2024; 21(2):178-185. PubMed ID: 38423598
[TBL] [Abstract][Full Text] [Related]
7. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.
Stafford WC; Peng X; Olofsson MH; Zhang X; Luci DK; Lu L; Cheng Q; Trésaugues L; Dexheimer TS; Coussens NP; Augsten M; Ahlzén HM; Orwar O; Östman A; Stone-Elander S; Maloney DJ; Jadhav A; Simeonov A; Linder S; Arnér ESJ
Sci Transl Med; 2018 Feb; 10(428):. PubMed ID: 29444979
[TBL] [Abstract][Full Text] [Related]
8. Combined Targeting of the Glutathione and Thioredoxin Antioxidant Systems in Pancreatic Cancer.
Fazzari F; Chow S; Cheung M; Barghout SH; Schimmer AD; Chang Q; Hedley D
ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1070-1078. PubMed ID: 36407947
[TBL] [Abstract][Full Text] [Related]
9. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity.
Prasad CB; Oo A; Liu Y; Qiu Z; Zhong Y; Li N; Singh D; Xin X; Cho YJ; Li Z; Zhang X; Yan C; Zheng Q; Wang QE; Guo D; Kim B; Zhang J
Nat Commun; 2024 May; 15(1):4667. PubMed ID: 38821952
[TBL] [Abstract][Full Text] [Related]
10. Enzyme-mediated depletion of l-cyst(e)ine synergizes with thioredoxin reductase inhibition for suppression of pancreatic tumor growth.
Kshattry S; Saha A; Gries P; Tiziani S; Stone E; Georgiou G; DiGiovanni J
NPJ Precis Oncol; 2019; 3():16. PubMed ID: 31231686
[TBL] [Abstract][Full Text] [Related]
11. [Thioredoxin-reductase in fibroblasts of human dermis in the process of aging.].
Tasakova OS; Golubtzova NN; Gunin AG
Adv Gerontol; 2023; 36(4):584-591. PubMed ID: 38010188
[TBL] [Abstract][Full Text] [Related]
12. Microsomal glutathione transferase 1 controls metastasis and therapeutic response in melanoma.
Zhang J; Ye ZW; Chakraborty P; Luo Z; Culpepper J; Aslam M; Zhang L; Johansson K; Haeggström JZ; Xu J; Olsson M; Townsend DM; Mehrotra S; Morgenstern R; Tew KD
Pharmacol Res; 2023 Oct; 196():106899. PubMed ID: 37648102
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of the thioredoxin and glutathione systems in cancer and HIV.
Benhar M; Shytaj IL; Stamler JS; Savarino A
J Clin Invest; 2016 May; 126(5):1630-9. PubMed ID: 27135880
[TBL] [Abstract][Full Text] [Related]
14. Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer.
Hatem E; Azzi S; El Banna N; He T; Heneman-Masurel A; Vernis L; Baïlle D; Masson V; Dingli F; Loew D; Azzarone B; Eid P; Baldacci G; Huang ME
J Natl Cancer Inst; 2018 Nov; ():. PubMed ID: 30462268
[TBL] [Abstract][Full Text] [Related]
15. [Thioredoxin interacting protein in fibroblasts of human dermis in the process of aging.].
Tasakova OS; Golubtzova NN; Gunin AG
Adv Gerontol; 2023; 36(6):825-832. PubMed ID: 38426919
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin.
Sabatier P; Beusch CM; Gencheva R; Cheng Q; Zubarev R; Arnér ESJ
Redox Biol; 2021 Nov; 48():102184. PubMed ID: 34788728
[TBL] [Abstract][Full Text] [Related]
17. ROS and radiotherapy: more we care.
Sonveaux P
Oncotarget; 2017 May; 8(22):35482-35483. PubMed ID: 28415657
[No Abstract] [Full Text] [Related]
18. Enhancement of Radiation Response in Breast Cancer Stem Cells by Inhibition of Thioredoxin- and Glutathione-Dependent Metabolism.
Rodman SN; Spence JM; Ronnfeldt TJ; Zhu Y; Solst SR; O'Neill RA; Allen BG; Guan X; Spitz DR; Fath MA
Radiat Res; 2016 Oct; 186(4):385-395. PubMed ID: 27643875
[TBL] [Abstract][Full Text] [Related]
19. Expression of the thioredoxin system in an in vivo-like cancer cell environment upon auranofin treatment.
Bhatia M; Lovitt CJ; Raninga PV; Avery VM; Di Trapani G; Tonissen KF
Eur J Cell Biol; 2016 Oct; 95(10):378-388. PubMed ID: 27567536
[TBL] [Abstract][Full Text] [Related]
20. Colorectal Cancer Stem Cells and Targeted Agents.
Zhao H; Han R; Wang Z; Xian J; Bai X
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
